<div id="readability-page-1"><article>Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer PreventionMELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on innovative formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen— the active components in Propanc’s lead asset, PRP — addressing critical challenges in stability, storage, freeze/thaw cycling, and global transport. These advancements overcome longstanding barriers in developing viable pharmaceutical compositions of these proenzymes for biomedical applications, including cancer and other chronic diseases. “Filing four provisional patent applications in such a short timeframe underscores our relentless drive to protect and expand our groundbreaking proenzyme technology,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “As these applications advance to national phase entry across major global markets, we expect to more than double our IP portfolio — from approximately 90 to over 200 patents — covering compositions, formulations, treatment methods, and new therapeutic indications.” This rapid IP expansion reinforces Propanc’s commanding position in a novel therapeutic paradigm: using proenzymes to target and prevent metastasis from solid tumors — particularly aggressive, poorly differentiated cancers where options remain limited and standard treatments often carry severe side effects. “These patents applications will secure our leadership for the next two decades in a field with enormous unmet need,” Mr. Nathanielsz continued. “We’re building an unassailable foundation to propel our lead asset, PRP, into a landmark Phase 1b First-In-Human study in advanced cancer patients. Preparations are advancing rapidly, and we anticipate further exciting updates on our clinical pathway and broader pipeline in the near term.” Propanc’s PRP is a proprietary intravenous formulation designed to selectively attack cancer stem cells and circulating tumor cells while sparing healthy tissue — offering potential as a long-term therapy to halt recurrence and metastasis without the toxicity of conventional chemotherapy or radiation. About Propanc Biopharma, Inc. Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread. More information: www.propanc.com Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. Company: Propanc Biopharma, Inc. James Nathanielsz +61-3-9882-0780 info@propanc.com Investor Contact: irteam@propanc.com <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME16QXlNaU0zTXpreU5qUTJJekl5T1RFeE1UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME16QXlNaU0zTXpreU5qUTJJekl5T1RFeE1UST0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTdmMzYyMzAtZjIyNy00ZmNlLTg3NDYtOGQ0M2IyNDI0YmYxLTEzMDI2NjItMjAyNi0wMS0yNy1lbg==/tiny/Propanc-Biopharma-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTdmMzYyMzAtZjIyNy00ZmNlLTg3NDYtOGQ0M2IyNDI0YmYxLTEzMDI2NjItMjAyNi0wMS0yNy1lbg==/tiny/Propanc-Biopharma-Inc-.png"/></article></div>

PPCB

SBIO

Propanc Biopharma, Inc. has filed its fourth provisional patent application in two months, aiming to double its patent portfolio to over 200 worldwide. This application focuses on innovative formulations of pancreatic proenzymes, addressing challenges in stability and transport for biomedical applications, particularly in cancer treatment. CEO James Nathanielsz emphasized the company's commitment to protecting its proenzyme technology, which targets cancer stem cells and aims to prevent metastasis. The company is preparing for a Phase 1b study of its lead asset, PRP, designed to offer a less toxic alternative to conventional cancer therapies.

StockTitan

Propanc Biopharma

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations | PPCB Stock News